WO2004105702A3 - Foamable pharmaceutical compositions and methods for treating a disorder - Google Patents

Foamable pharmaceutical compositions and methods for treating a disorder Download PDF

Info

Publication number
WO2004105702A3
WO2004105702A3 PCT/US2004/016733 US2004016733W WO2004105702A3 WO 2004105702 A3 WO2004105702 A3 WO 2004105702A3 US 2004016733 W US2004016733 W US 2004016733W WO 2004105702 A3 WO2004105702 A3 WO 2004105702A3
Authority
WO
WIPO (PCT)
Prior art keywords
foamable
disorder
treating
methods
pharmaceutical compositions
Prior art date
Application number
PCT/US2004/016733
Other languages
French (fr)
Other versions
WO2004105702A2 (en
Inventor
Karl F Popp
Edward R Yuhas
Original Assignee
Stiefel Laboratories
Karl F Popp
Edward R Yuhas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004105702(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2004242963A priority Critical patent/AU2004242963B2/en
Priority to MXPA05012842A priority patent/MXPA05012842A/en
Priority to BRPI0410721-7A priority patent/BRPI0410721A/en
Priority to KR1020057022487A priority patent/KR101141220B1/en
Priority to JP2006533458A priority patent/JP4871728B2/en
Application filed by Stiefel Laboratories, Karl F Popp, Edward R Yuhas filed Critical Stiefel Laboratories
Priority to PL04753550T priority patent/PL1633368T3/en
Priority to AT04753550T priority patent/ATE533493T1/en
Priority to EP04753550A priority patent/EP1633368B1/en
Priority to CA2527499A priority patent/CA2527499C/en
Priority to ES04753550T priority patent/ES2377064T3/en
Publication of WO2004105702A2 publication Critical patent/WO2004105702A2/en
Publication of WO2004105702A3 publication Critical patent/WO2004105702A3/en
Priority to IL172082A priority patent/IL172082A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Abstract

Novel compositions of matter comprising a foamable delivery system are provided. Novel methods for treating a disease, disorder, or condition using the novel compositions, are further provided. Novel methods for making and delivering a foamable pharmaceutical composition are also provided. While the novel compositions and foamable drug delivery system may be utilized for administration of a wide variety of drugs to epithelialtissues, to treat a wide variety of diseases, disorders, or conditions, the inventive compositions and foamable drug delivery systems are particularly useful for the dermatological administration of corticosteroids and antifungal agents.
PCT/US2004/016733 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder WO2004105702A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
ES04753550T ES2377064T3 (en) 2003-05-28 2004-05-27 Pharmaceutical compositions in foam form and methods for treating a disorder
AT04753550T ATE533493T1 (en) 2003-05-28 2004-05-27 FOAMING PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISEASE
BRPI0410721-7A BRPI0410721A (en) 2003-05-28 2004-05-27 foamable pharmaceutical compositions and methods for treating a disorder
KR1020057022487A KR101141220B1 (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder
JP2006533458A JP4871728B2 (en) 2003-05-28 2004-05-27 Foaming pharmaceutical composition and disorder treatment method
AU2004242963A AU2004242963B2 (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder
PL04753550T PL1633368T3 (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder
MXPA05012842A MXPA05012842A (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder.
EP04753550A EP1633368B1 (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder
CA2527499A CA2527499C (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder
IL172082A IL172082A0 (en) 2003-05-28 2005-11-21 Foamable pharmaceutical compositions and methods for treating a disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/445,487 2003-05-28
US10/445,487 US7186416B2 (en) 2003-05-28 2003-05-28 Foamable pharmaceutical compositions and methods for treating a disorder

Publications (2)

Publication Number Publication Date
WO2004105702A2 WO2004105702A2 (en) 2004-12-09
WO2004105702A3 true WO2004105702A3 (en) 2005-05-06

Family

ID=33450867

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/016733 WO2004105702A2 (en) 2003-05-28 2004-05-27 Foamable pharmaceutical compositions and methods for treating a disorder

Country Status (15)

Country Link
US (2) US7186416B2 (en)
EP (1) EP1633368B1 (en)
JP (1) JP4871728B2 (en)
KR (1) KR101141220B1 (en)
CN (1) CN1794998A (en)
AT (1) ATE533493T1 (en)
AU (1) AU2004242963B2 (en)
BR (1) BRPI0410721A (en)
CA (1) CA2527499C (en)
ES (1) ES2377064T3 (en)
IL (1) IL172082A0 (en)
MX (1) MXPA05012842A (en)
PL (1) PL1633368T3 (en)
WO (1) WO2004105702A2 (en)
ZA (1) ZA200510388B (en)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
WO2004037225A2 (en) 2002-10-25 2004-05-06 Foamix Ltd. Cosmetic and pharmaceutical foam
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
CA2540085C (en) 2003-09-29 2010-11-16 Bruce Michael Koivisto High alcohol content gel-like and foaming compositions
US8940321B2 (en) 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US8030362B2 (en) 2003-12-12 2011-10-04 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
US20050255048A1 (en) * 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
CA2571389C (en) * 2004-07-06 2011-10-04 International Paper Company Paper substrates containing an antimicrobial compound as well as methods of making and using the same
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
US20060137684A1 (en) * 2004-12-01 2006-06-29 Celeste Evans Compositions and methods of treating irritation and kit therefor
DE102004062775A1 (en) 2004-12-21 2006-06-29 Stockhausen Gmbh Alcoholic pump foam
EP3292757A1 (en) 2005-03-07 2018-03-14 Deb IP Limited High alcohol content foaming compositions with silicone-based surfactants
JP2008540511A (en) 2005-05-09 2008-11-20 フォーミックス エルティーディー． Sugar foaming composition
PL2526930T3 (en) * 2005-06-01 2014-05-30 Glaxosmithkline Ip Dev Ltd Vitamin formulation
US8846154B2 (en) 2005-06-07 2014-09-30 S.C. Johnson & Son, Inc. Carpet décor and setting solution compositions
US20100154146A1 (en) 2008-07-02 2010-06-24 S.C. Johnson & Son, Inc. Carpet decor and setting solution compositions
WO2007099396A2 (en) * 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
US7651990B2 (en) 2005-06-13 2010-01-26 3M Innovative Properties Company Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use
US20070027119A1 (en) * 2005-07-29 2007-02-01 Ahmed Fahim U Antibacterial composition and method of use
US8778369B2 (en) * 2005-07-29 2014-07-15 Delaval Holding Ab Barrier film-forming compositions and methods of use
CA2626208A1 (en) * 2005-10-24 2007-05-03 Collegium Pharmaceutical, Inc. Topical pharmaceutical foam composition
AU2007273935B2 (en) 2006-03-31 2011-08-18 Stiefel Research Australia Pty Ltd Foamable suspension gel
EP2051697A2 (en) * 2006-07-05 2009-04-29 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
ES2393761T3 (en) 2006-07-14 2012-12-27 Stiefel Research Australia Pty Ltd Pharmaceutical fatty acid foam
AU2007275815A1 (en) * 2006-07-18 2008-01-24 Wirra Ip Pty. Ltd. Immune response modifier formulations
DE102006034883A1 (en) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Composition, useful to treat inflammatory skin disease, e.g. psoriasis, comprises mometasone furoate, water, a combination of aromatic alcohol and a solvent e.g. alkoxylated fatty-alcohol and/or aliphatic alcohol, and further additives
GB2443161B (en) * 2006-10-28 2011-03-23 Nupharm Lab Ltd Clobetasol spray
GB2443162B (en) * 2006-10-28 2011-02-09 Nupharm Lab Ltd Betamethasone spray
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
PL1986473T3 (en) * 2007-04-03 2017-07-31 Tsinghua University Organic electroluminescent device
FR2915097B1 (en) * 2007-04-18 2012-09-28 Fabre Pierre Dermo Cosmetique ANTIFUNGAL FOAM BASED ON CICLOPIROXOLAMINE AND ZINC PYRITHIONE AND ITS MEDICAL AND COSMETIC APPLICATIONS.
JP2010524976A (en) * 2007-05-04 2010-07-22 ザ プロクター アンド ギャンブル カンパニー Antibacterial composition, product and method of use
GB0712308D0 (en) * 2007-06-25 2007-08-01 Kind Group Ltd An inhalable composition
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
DE102007039954A1 (en) * 2007-08-23 2009-02-26 Henkel Ag & Co. Kgaa Reductive discoloration of keratinous fibers
US8802060B2 (en) * 2007-10-01 2014-08-12 Colgate-Palmolive Company Foamable fluoride oral care composition
WO2009084020A2 (en) * 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
EP2242476A2 (en) * 2008-01-14 2010-10-27 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20110224312A1 (en) * 2008-11-17 2011-09-15 Wayne State University Engineering porous particles of water soluble therapeutics for pressurized metered-dose inhaler formulations
CA2760186C (en) 2009-04-28 2019-10-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
EP2343300A1 (en) * 2009-12-05 2011-07-13 Cognis IP Management GmbH Anionic isosorbide derivatives and their use (II)
US8802058B2 (en) * 2010-04-19 2014-08-12 Gelmed, Llc Pharmaceutical compositions and methods for administering the same
EP2672968A4 (en) * 2010-10-26 2016-07-13 Quinnova Pharmaceuticals Inc Econazole composition and methods of treatment therewith
US9345720B2 (en) 2010-10-26 2016-05-24 Exeltis Usa Dermatology, Inc. Composition and method for treating wounds
IT1402786B1 (en) * 2010-11-19 2013-09-18 Fidia Farmaceutici PHARMACEUTICAL COMPOSITIONS WITH ANTIBACTERIAL AND CICATRIZING ACTIVITIES
US9089129B2 (en) 2011-10-07 2015-07-28 American Sterilizer Company Non-aerosol foaming alcohol hand sanitizer
TW201329226A (en) * 2011-11-30 2013-07-16 Basf Se Composition for dissolving and/or inhibiting deposition of scale on a surface of a system
CN102641283B (en) * 2012-04-07 2013-05-08 张红 Medicine for treating scurf and preparing method thereof
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
CN104703585A (en) 2012-10-09 2015-06-10 宝洁公司 Method of identifying synergistic cosmetic combinations
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
EP2938327B1 (en) 2012-12-26 2017-12-06 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
EP3020392A4 (en) 2013-07-11 2016-12-28 Pola Pharma Inc External-use composition producing foamed state upon use
CN104032590A (en) * 2014-05-14 2014-09-10 江苏金秋弹性织物有限公司 Dyeing processing technology for active carbon and nano-silver synergically-antibacterial fabric tapes
KR102572389B1 (en) * 2014-12-24 2023-08-29 가부시키가이샤 폴라 파마 External composition for screen foamers
FR3041538B1 (en) * 2015-09-29 2018-11-30 Galderma Research & Development NON-RINSE CHEMICAL FOAM CONTAINING CLOBETASOL PROPIONATE AND USE THEREOF IN THE TREATMENT OF PSORIASIS
JP2018538327A (en) * 2015-12-15 2018-12-27 セラピューティクス インク．Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． Halobetasol foam composition and method of use
CN105486778B (en) * 2016-01-25 2017-11-03 齐炼文 The metabolic markers of stable angina cordis and acute coronary syndrome are distinguished in diagnosis
CA3021325A1 (en) 2016-04-20 2017-10-26 S.C. Johnson & Son, Inc. Foaming antimicrobial compositions
MX2018013761A (en) 2016-05-11 2019-09-09 Bayer Healthcare Llc Whipped formulations with desired sensory impact.
EP3454662A1 (en) 2016-05-11 2019-03-20 Bayer Healthcare LLC Thermal-stable whipped formulations
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN111315346A (en) 2017-05-11 2020-06-19 拜尔斯多夫股份公司 Gel formulations
US10660838B2 (en) 2017-06-23 2020-05-26 The Procter & Gamble Company Composition and method for improving the appearance of skin
CN112437657A (en) 2018-07-03 2021-03-02 宝洁公司 Method of treating skin conditions
US20210196631A1 (en) * 2018-08-28 2021-07-01 Glenmark Pharmaceuticals Limited Container system and pharmaceutical foam composition comprising betamethasone
CN115398198A (en) 2020-03-24 2022-11-25 宝洁公司 Method for testing skin samples
EP4157206A1 (en) 2020-06-01 2023-04-05 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110809A (en) * 1988-03-21 1992-05-05 Bristol-Myers Squibb Company Antifungal gel formulations
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
EP0813413B1 (en) * 1995-03-03 2003-11-05 Medeva PLC Corticosteroid-containing foam

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4838286A (en) * 1971-09-18 1973-06-05
US4018918A (en) 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
US4141472A (en) * 1976-07-19 1979-02-27 Spitzer Joseph G Aerosol container with gas-permeable membrane
US4141417A (en) * 1977-09-09 1979-02-27 Institute Of Gas Technology Enhanced oil recovery
US4420484A (en) 1979-08-13 1983-12-13 Sterling Drug Inc. Basic amino or ammonium antimicrobial agent-polyethylene glycol ester surfactant-betaine and/or amine oxide surfactant compositions and method of use therof
AU565146B2 (en) 1983-10-24 1987-09-03 Connetics Australia Pty Ltd Foamable biocide composition
EP0190158A1 (en) 1984-06-21 1986-08-13 Soltec Research Pty. Ltd. Aerosol product
US5002680A (en) 1985-03-01 1991-03-26 The Procter & Gamble Company Mild skin cleansing aerosol mousse with skin feel and moisturization benefits
US4806262A (en) 1985-08-14 1989-02-21 The Procter & Gamble Company Nonlathering cleansing mousse with skin conditioning benefits
US5446028A (en) * 1985-12-12 1995-08-29 Dermik Laboratories, Inc. Anti-acne method and composition
JPS62273912A (en) * 1986-05-21 1987-11-28 Kao Corp Aerosol agent to be applied to human body
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
US4882182A (en) 1987-01-08 1989-11-21 Soltec Research Pty. Ltd. Aerosol product
US4847068A (en) 1987-08-06 1989-07-11 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US4885354A (en) 1987-10-29 1989-12-05 Ciba-Geigy Corporation Epoxy resin compositions
US5143717A (en) 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
AU619256B2 (en) 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
DE69030698T2 (en) 1989-03-17 1997-10-02 Taisho Pharmaceutical Co Ltd AEROSOL COMPOSITION FOR EXTERNAL USE
AU629670B2 (en) * 1989-07-28 1992-10-08 Hisamitsu Pharmaceutical Co., Inc. Foamed aerosol preparation
IL95952A0 (en) 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
JP3140460B2 (en) 1990-09-03 2001-03-05 ソルテック リサーチ プロプライアタリィ リミティド Concentrated aerosol space spray
US5935554A (en) 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
FR2677369B1 (en) 1991-06-05 1994-09-16 Promotion Rech Innovation Tec AEROSOL FOAM.
DE4129756C2 (en) 1991-09-04 1995-06-29 Mannesmann Ag Metallurgical vessel for a DC arc device
GB2260079B (en) * 1991-10-01 1995-08-09 American Cyanamid Co Pharmaceutical composition containing felbinac
US5211317A (en) 1992-06-18 1993-05-18 Diamond George Bernard Low pressure non-barrier type, valved dispensing can
ZA94170B (en) 1993-01-20 1995-03-15 Soltec Res Pty Ltd Ectoparasiticidal formulation
US5570296A (en) 1994-03-30 1996-10-29 Apple Computer, Inc. System and method for synchronized presentation of video and audio signals
US5679324A (en) 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
US5776430A (en) 1994-11-01 1998-07-07 Calgon Vestal, Inc. Topical antimicrobial cleanser containing chlorhexidine gluconate and alcohol
JPH08175982A (en) * 1994-12-21 1996-07-09 Lederle Japan Ltd 4-biphenylyl acetate composition
US5783202A (en) 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
EP0738510A3 (en) 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
FR2740685B1 (en) 1995-11-08 1998-01-23 Pf Medicament TOPICAL FOAMING PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOSIS, INDUCED BY OVAL PITYROSPORUM
US5788155A (en) 1996-06-28 1998-08-04 S. C. Johnson & Son, Inc. Air freshener dispenser device with dual cartridge capacity
DE19631221C2 (en) 1996-08-02 1999-07-01 Beiersdorf Ag Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
AUPO688997A0 (en) 1997-05-20 1997-06-12 Soltec Research Pty Ltd Sunscreen composition
CA2293622C (en) 1997-06-13 2007-08-21 Taisho Pharmaceutical Co., Ltd. Aerosol preparation
GB2327344A (en) 1997-07-18 1999-01-27 Ninh Thuy On Pharmaceutical compositions containing phenytoin and either an azole anti-fungal/anti-bacterial agent and/or a silver salt for topical application
US5965500A (en) 1997-07-24 1999-10-12 Levers Brothers Company, Division Of Conopco, Inc. Stable liquid composition comprising high levels of emollients
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
DE59808313D1 (en) 1998-02-02 2003-06-12 Boehringer Ingelheim Vetmed USE OF COMBINATIONS OF ACTIVE SUBSTANCES FROM ANTIBIOTICS AND TERPENIC PLANT EXTRACTS IN ANIMAL MEDICINE
US6030931A (en) 1998-02-03 2000-02-29 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Foaming cleansing skin product
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
AUPP310798A0 (en) 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264964B1 (en) 1999-04-14 2001-07-24 Conopco, Inc. Foaming cosmetic products
AUPQ002999A0 (en) 1999-04-29 1999-05-20 Soltec Research Pty Ltd Non-aqueous shampoo composition
US6547063B1 (en) 2000-10-10 2003-04-15 The Procter & Gamble Company Article for the delivery of foam products
FR2820038B1 (en) 2001-01-29 2004-07-02 Dermaconcept Jmc DERMATOLOGICAL COMPOSITION FOR VETERINARY USE COMPRISING A SPHINGOID BASE
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
WO2004064833A1 (en) 2003-01-24 2004-08-05 Connetics Australia Pty Ltd. Clindamycin phosphate foam
CN101945762B (en) * 2008-02-14 2013-11-06 名古屋油化株式会社 Sound absorbing skin material and sound absorbing material utilizing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110809A (en) * 1988-03-21 1992-05-05 Bristol-Myers Squibb Company Antifungal gel formulations
EP0813413B1 (en) * 1995-03-03 2003-11-05 Medeva PLC Corticosteroid-containing foam
US6253762B1 (en) * 1995-04-14 2001-07-03 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Drug information on LUXIQ(R)", CONNETICS, September 2001 (2001-09-01), XP003010341, Retrieved from the Internet <URL:http://www.luxiq.com> *

Also Published As

Publication number Publication date
CA2527499A1 (en) 2004-12-09
JP4871728B2 (en) 2012-02-08
KR101141220B1 (en) 2012-05-07
ZA200510388B (en) 2006-12-27
ES2377064T3 (en) 2012-03-22
PL1633368T3 (en) 2012-04-30
CA2527499C (en) 2012-01-24
KR20060023972A (en) 2006-03-15
EP1633368A4 (en) 2007-03-14
US7829107B2 (en) 2010-11-09
EP1633368B1 (en) 2011-11-16
AU2004242963B2 (en) 2009-05-28
US20040241099A1 (en) 2004-12-02
ATE533493T1 (en) 2011-12-15
IL172082A0 (en) 2009-02-11
MXPA05012842A (en) 2006-05-17
US20070059253A1 (en) 2007-03-15
BRPI0410721A (en) 2006-06-20
EP1633368A2 (en) 2006-03-15
WO2004105702A2 (en) 2004-12-09
US7186416B2 (en) 2007-03-06
JP2007500235A (en) 2007-01-11
CN1794998A (en) 2006-06-28
AU2004242963A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
WO2004105702A3 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
WO2002011711A3 (en) Formulations of mometasone and a bronchodilator for pulmonary administration
WO2002096435A3 (en) Skin-permeable composition comprising a selective cyclooxygenase-2 inhibitor a monohydric alcohol
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
CA2558896A1 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
WO2003080022A3 (en) Analgesics for nasal administration
WO2005105067A3 (en) Aqueous solutions comprising prednisolone and a cyclodextrin derivative
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
WO2006124681A3 (en) Oral drug delivery system and methods of use thereof
WO2004043378A3 (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2005112967A3 (en) Anticancer activity of chios mastic gum
WO2006060325A3 (en) Coated drug delivery formulations
WO2006097725A3 (en) Pharmaceutical compositions comprising microparticles for delivery into neurons
WO2004066983A3 (en) Controlled release of highly soluble agents
GB2446341A (en) Method and system for transdermal drug delivery
WO2008049903A3 (en) Wide-area parasystemic treatment of skin related conditions
TW200509985A (en) Drug delivery system for sub-Tenon administration of fine particles
WO2004090537A3 (en) Methods to individualize combination therapy
WO2005065372A3 (en) Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 172082

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057022487

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006533458

Country of ref document: JP

Ref document number: 20048144040

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2527499

Country of ref document: CA

Ref document number: PA/a/2005/012842

Country of ref document: MX

Ref document number: 2004242963

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1366/MUMNP/2005

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004242963

Country of ref document: AU

Date of ref document: 20040527

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004242963

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/10388

Country of ref document: ZA

Ref document number: 200510388

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2004753550

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004753550

Country of ref document: EP

Ref document number: 1020057022487

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0410721

Country of ref document: BR